BRAF and non-small cell lung carcinoma: By leveraging this valuable resource, we aimed to gain insights into the clinical landscape of BRAF-mutant tumors, with a focus on NSCLC, and identify potential differences in patient outcomes across mutation classes, addressing current knowledge gaps.